Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for interesting info. Please send your info to some American Diabetes Association(ADA) literature sites dealing with Chronic Kidney Disease and Risk Management—Screening and Treatment. Some links:
1). Kidney Disease: Improving Global Outcomes (KDIGO).
Diabetes Care 2022;45:3075-3090
2). Clin Diabetes 2024;42:212-213 (doi:10.2337/cd24-a011)
3). http://diabetesjournals.org/clinical/article-pdf/42/2/212756314/diaclincd24a011.pdf
CYTK chart?
See https://www.evernorth.com/advocate for complaint and further information. My own views, in part, are posted on the AMRN board earlier today. Any resemblance between the Titanic and an iceberg is purely coincidental.
Cigna, Express Scripts and its sub sue FTC today in Missouri.
The complaint raises issues re a July 2024 Report published by FTC about high drug prices, and asserts the FTC has exceeded its power in issuing the Report.
https://www.prnewswire.com look for Express Scripts
www.wsj.com
Reuters, Bloomberg, Fierce Biotech Health also cover the issues raised in the 30 page complaint.
# sleven, it seems there are a number of lawyers with that first and last name set forth in the order of admission pro hac vice issued by the Magistrate Judge in the New Jersey antitrust action. Have you ascertained/fixed which one, among those that have desirable qualifications and experience?
Readers here will find paragraphs 23-45 of the complaint particularly interesting. I have not read further yet.
Express Scripts is suing FTC, seeks to stop FTC investigation of facts that allegedly caused large losses in CVS and other pharmacies, PBMs, insurance companies. It says FTC should actually support attempts by Express Scripts to lower drug prices. A Constitutional issue is raised via allegation that FTC has no authority to issue its July Report, and demands that it be retracted and withdrawn.
Looks like both FTC and DOJ need to investigate the unfair competition, if not outright fraud, by which the generics have attempted to enter AMRN’s triglycerides reduction and CVD market. GEHA, the large government employees insurance company, is said to have “sold” its insurance plan covering Vascepa to Express Scripts in light of loss on bid to continue its coverage at CVS. My out of pocket cost for brand Vascepa has risen markedly from the $9-15 for a 3 month supply I paid for many years.
See https://www.evernorth.com/advocate
Evernorth is a subsidiary of Cigna. Suit was filed in Missouri.
What news accounts for this rise in BBLG’s share price? $1.72 real time.
Large Swiss study that appears totally funded by BPs; no funding reported by AMRN re use of IPE in study. Results reported from use of IPE on discharge from hospital of patients 1 year after affliction of first CVD. More details available than reported above.
30 pages if printed both sides.
Barron’s: Ellison of ORCL is buying all the Blackwells he can get for servers and a new, cloud AI supercomputer. Besides a 800-megawatt OCI data center facility—“acres of NVDA GPU clusters”—currently being built, an even larger facility is in design stage, planned to be powered by a nuclear reactor. NVDA and ORCL announced this past week that OCI would deploy the largest-ever GPU “compute cluster” with 2025 availability. OCI is Oracle Cloud Infrastructure. More details at 9/16/2024 Barron’s, p. 25.
kiwi, I behave a faint memory of Tang(?) recently closing position in AMRN while others are piling in, something more to check out.
Do any of GILD’s ongoing clinical trials investigate the potential of safe and effective subcutaneous administration of Lenacapavir, using HALO’s Enhanze technology?
JR, PL, T10: I never expected to read about what the Congress and PTO are doing to screw up ( change) the patent law concerning obviousness-type double patenting and effect of terminal disclaimers in JAMA. The 9/10/2014 JAMA I earlier linked contains such an article. Sample quotes:
“…A recent USPTO proposed rule would establish that if any claim in a patent is found invalid, all patents linked to it via terminal disclaimers would become unenforceable. A bipartisan bill in Congress would permit patent holders to enforce only 1 patent per group connected by terminal disclaimers in litigation with generic and biosimilar manufacturers.”
“…Reducing the size of patent thickets should facilitate market entry of generic and biosimilar drugs closer to expiration of the patent on the underlying active ingredient, thereby improving competition and patient access to affordable drugs.”
GILD: Twice yearly Lenacapavir injection for HIV-1 infections was “superior,” beats results from once daily results from Truvada. IDMC recommended that Phase 3 trial of Lencapavir be stopped.
Featured on CNBC-TV this morning, 8:40 a.m. time frame.
I hit the wrong button, sent the incomplete message and it’s bedtime here anyway. I hope you can access the 3-page article from the on-line link above or the 9/10/2024 print edition. Worth reading, IMO, for an introduction to new markets, new blood tests, fast developing commercial technology that augurs well for both CDMO and HALO.
I’m wondering now whether the above blood tests that “replace” more invasive tests, as discussed in JAMA, relate in any way to the delays in reporting follow-up results from the veterans and other patients in the completed U. Wisconsin BRAVE trial where analysis is ongoing or continuing. Did I read end of September?
There were a record-breaking 8500 in-person attendees at 2024 AAIC in Philadelphia.
doi:10.1001/jama.2024.13816
A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke—Highlights From the AAIC
After learning that Avid Bioservices is not really the same as, or parent of, or related to Avid Radiopharmaceuticals (LLY), the above article provided this reader with news from the recent AAIC session in Philadelphia. Significant observations here for both HALO and CDMO, IMO:
Anent the above title:…”10 years ago, there was no thought that it would be possible to actually diagnose this brain disease in blood taken from your arm.” That blood “contains plasma biomarkers, specifically phosphorylation tau
…”we’ve seen novel antiamyloid treatments with an easier mode of administration, injected subcutaneously instead of having to be infused, as is required with [commercial, FDA-approved] donanemab [Kisunla] and lecanemab[Leqembi]….
But also very important are the other Alzheimer’s disease targets, like anti-tau and anti-inflammatory treatments and synaptic repair
GS, per Solomon on CNBC-TV a few minutes ago, is well positioned for growth in its wealth management business. Let’s see if GS lifts its AMRN PT from $ 1.00/share.
The market seems to have turned more + from a lousy open today for our portfolios. Right now, we’re + $55,190. Can’t say AMRN is helping any tho’.
Dew has a table of acquisition data on Biotech Value board. The premium was 101% to AMLN market price in late June 2012.
I think Denner was in charge, COO, of the biotech portion of Icahn’s portfolio at the time. Sometime earlier, AD left MS to join Icahn.
Source of that info didn’t say that acquisition occurred months ago. Old news. Delete this post and previous post.
BSX acquires AXON, a neuromodulation company.
Alex Denner was on the BOD of AMLN when its CEO put AMLN up for sale via an auction.
Is there a difference between “blueprint” and “plan”?
LBL, what data are you waiting to play out, from the MDCO plan and NVS purchase of MDCO 4-5 years ago? It looks like its FDA-approved inclisiran has been in the U.S. market for ~ 3-4 years. What is that plan?
NVS has now seen what that drug does for many of the same indications Vascepa has, albeit with substantial TV advertising compared to Vascepa 0-advertising(except for the substantial number of journal articles we have seen links to here). Is the relative insured cost of inclisiran vis a vis Vascepa a data issue? Same question re AEs.
MDCO has a pipeline of other molecules in pre-clinical or clinical trials. Is that the data you are waiting for?
I looked for data from any clinical or commercial use of Vascepa in conjunction with inclisiran in patients—nothing turned up there for me.
..??? If “Apple is not in the pharmaceutical business”, how does it lease Vascepa to anyone? Apple did have a healthcare unit, maybe it still does……Apple watch records blood pressure, new I-Pods have utility as hearing aids…..
With our few 1000s of profitable AVXL LTCG shares, I’m still waiting for those peer-reviewed journal results CM mentioned a time or two. My “Weinstein event” referred to an alert, stating Harvey had been hospitalized with a heart attack. Life, and message boards, are stressful for many people, AMRN shareholders included. Thanks for your calm response.
I used 4OurR’s link. I heard everything on I-Pad. The CEO’s accent/native language is still difficult for me. I’ll read the transcript for any needed clarification, or the PR that I just printed.
I read what was written on the slides today while listening to what was said by CM. What does WGT mean? An abbreviation for some kind of a Weinstein event?
The “or” could be used to introduce an additional alternative trial.
Your last 3 paragraphs are very likely to describe why that Centene- owned subsidiary H entered a confidential settlement earlier in this proceeding, involving unknown $$$.
Your narration is exactly how I view Hikma’s arguments—now Teva’s arguments as well in light of its earlier motion. No generic wants to return to any District Court where discovery proceeds in the manner you suggest and in the manner I suggested earlier today that got rmb all excited. I do think that having DOJ, Antitrust Division and possibly Solicitor General potentially involved would be advantageous.
Do you have an opinion about whether consolidation of the Trenton and Wilmington cases is the best way to force settlement (rather than litigation) of the various issues presented in the shortest time? Amarin has already said it wants to file an amended complaint( Amarin now has new counsel involved in current Hikma appeal); what allegations, issues and requested relief that any amended complaint might comprise is an open question, IMO.
Marjac, Hikma does not seem to deem the Amarin v. Hikma et al case that we shareholders attempted to participate in ( page I, Related Cases, “No” ) as “any related or prior cases…”. Yet the Hikma petition refers to that case several times as the originating reason why Hikma is before the Court a second time( e.g., pages 6 and 17).
Further, “…the Court should invite the government’s views.”( page 18, Conclusion ). The Court( like Hikma and Amarin) is already aware of the Amarin shareholder views, but our lack of standing to raise the “fraud on the Court” issue seemed to preclude a judgment or decision or opinion on that issue, notwithstanding Hazel-Atlas and FRCP….”at any time”. What now? Is the government, DOJ, S.G., Antitrust Division, aware of our views?
Be aware that the DOJ, Antitrust Division, issued a PR or FAQ some months ago wherein it stated it will investigate questions (via subpoena of witnesses and production of documents, no doubt) of collusive, anti-competitive, unfair, inequitable behavior and conduct in the pharmaceutical industry. Remember Norton v. Curtis, cited in the SH briefs and petition?
A preliminary injunction might be issued against Hikma, pending investigation/resolution of discovery and any trial that relates to those questions? A final order reinstating the patents invalidated in that first suit could issue, as Hazel-Atlas makes clear.
Much obliged, JRPac. Like sleven, I previously could not find a copy of that filed petition.
Long article today in WSJ print edition, pages A1 and A10, about side effects in younger men with apparently normal levels of testosterone who are prescribed testosterone for muscle-building by “sales” employees in Florida company. ABBV and its product mentioned toward end of article. Women also mentioned in article.
Looks like a Canadian case that we have briefly discussed here before; the rationale is good. I think we looked for a corresponding Fed.Cir. case, but didn’t find one.
See bas2020 article, “Shorting Innovation”, by Nancy Kim, Chicago-Kent School of Law, posted this morning on AVXL IHub board.
Likewise. It will be interesting to see if DOJ requests additional time to file a brief, or whether DOJ accepts Hikma’s invitation to do so. Amarin has a shortened time to respond, per my memory of Court rules. Will Seth Waxman return to the scene? Marjac served Waxman with a copy of our shareholder petition and brief, and the proceedings in Nevada and CAFC, I think.
More later re the potential evidence and issue arising from further discovery in the case. Will DOJ Antitrust or Civil divisions + Solicitor General weigh in regarding the inequitable conduct, fraud on the Courts, Hazel-Atlas, FRCP issues we shareholders raised about Hikma et al conduct that remain undecided?
Looks like selected quotes from author. Did author link the full petition, or did Hikma send a copy to him for publicity sake?
I’m staying with post-split 7560 shares of NVDA (bought in 2009) and a few 100s of shares NVDL. Decided today to add some AMDL shares to the 1000 AMD in portfolio since 2016. Our MAGS, WCBR and HACK ETF shares remain profitable, returning 46-126% even after recent declines in many of their respective weighted component shares, like CRWD.
Saw that interview also, bought a few 100 shares of AI after CEO finished talking, a little too soon perhaps. We’ll see “what gives” in next few days or months.
NVDA denied that DOJ subpoenaed anything today.